Comparing Rapid Stop vs. Gradual Reduction of Prednisone in Adults with Autoimmune or Inflammatory Disorders
Led by University Hospital, Basel, Switzerland · Updated on 2026-04-22
530
Participants Needed
16
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effects of stopping systemic glucocorticoid treatment quickly compared to gradually reducing the dose over 4 weeks in patients with inflammatory or autoimmune disorders. This trial is a placebo-controlled, multicenter, randomized study designed to compare rapid termination with a tapering regimen of prednisone. It aims to determine if abrupt stopping is not worse than tapering in terms of patient outcomes over six months.
Participants will be randomly assigned to one of two groups one group will receive prednisone with decreasing doses over 4 weeks following a specific tapering schedule, while the other group will stop glucocorticoid treatment abruptly and receive a matching placebo over the same period. Both patients and study staff will be unaware of the treatment allocation. The trial includes a stimulation test at the start, and patients will receive education on managing stress and symptoms related to low cortisol. Follow-up visits will occur mostly by phone at days 7, 35, 90, and 180 to ensure safety and monitor progress.
During the study, participants will be monitored for time to any incidence related to glucocorticoid withdrawal up to 6 months, with additional outcomes including health status, symptoms of low cortisol, and hospital stay length if applicable. Safety is a priority with early visits after stopping treatment and emergency medication provided. Researchers will also assess test performance and glucocorticoid doses taken for relapse or adrenal failure treatment. The total follow-up duration for participants is six months.
CONDITIONS
Brief Title
Taper Or Abrupt Steroid Stop: TOASSTtrial
Research Team
J
Jonas Rutishauser, Prof MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Able to provide informed consent by signing the consent form
Aged 18 years or older
Taking a daily glucocorticoid dose of 7.5 mg prednisone-equivalent or higher at enrollment
Receiving glucocorticoid therapy for at least 28 days with an average daily dose of 7.5 mg or more
Tapering of glucocorticoids is not required or no longer necessary to treat the underlying disease
You will not qualify if you...
Diagnosed with primary adrenal failure
Receiving systemic depot glucocorticoid treatments such as intramuscular or epidural injections
Unable to provide glucocorticoid cover treatment during stress situations
Unable or unwilling to give informed consent
Pregnant or breastfeeding women
Planning to become pregnant during the study
Female participants of childbearing potential not using reliable contraception throughout the study
Known or suspected to be non-compliant with study requirements
Unable to follow study procedures due to language, psychological, or cognitive issues
Participation in another investigational drug study within 30 days before or during this study
Previous enrollment in this study
Investigator or related persons enrolled in the study
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 4 weeks
Participants receive either prednisone in decreasing doses over 4 weeks or matching placebo administered over 4 weeks while blinded to treatment allocation.
1 baseline visit and 2 early follow-up visits at days 7 and 35
Follow-up
Duration - Up to 6 months
Participants are followed for safety and outcomes up to 6 months after treatment completion, mostly via telephone visits.
2 follow-up visits at days 90 and 180, mostly by telephone
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Using Advanced 7 Tesla MRI Brain Imaging to Understand How Filgotinib Relieves Pain in Adults with Rheumatoid Arthritis
Evaluating Safety and Early Effectiveness of NEUK203-215 Injection with Fludarabine and Cyclophosphamide in Adults 18 to 65 With Difficult-to-Treat Autoimmune Diseases in China
Phase 1 Study of Anitocabtagene Autoleucel for Treatment of Generalized Myasthenia Gravis with Dose Escalation and Expansion
Phase 1 Study Evaluating Safety and Dosage of JANX011 in Healthy Adults Aged 18 to 65
Comparing Rapid Stop vs. Gradual Reduction of Prednisone in Adults with Autoimmune or Inflammatory Disorders
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Glucocorticoid withdrawal and glucocorticoid-induced adrenal insufficiency: Study protocol of the randomized controlled «TOASST" (Taper Or Abrupt Steroid STop) multicenter trial.
Mathis Komminoth, Marc Y Donath, Matthias Hepprich...